Welcome to our dedicated page for Apogee Therapeutics SEC filings (Ticker: APGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apogee Therapeutics, Inc. filings document a clinical-stage biotechnology issuer focused on antibody programs for inflammatory and immunology indications. The company’s Form 8-K disclosures cover operating results, Regulation FD clinical-data presentations for zumilokibart (APG777), APG279 and APG333 development activity, and material agreements related to public common-stock offerings.
Proxy materials cover annual meeting matters, director elections, board composition, executive compensation, equity awards and shareholder voting. The filings also identify APGE common stock on The Nasdaq Global Market and provide recurring capital-structure, governance, clinical or regulatory, and financial disclosures tied to the company’s research and development model.
A holder of Apogee Therapeutics (symbol APGE) common stock filed a Form 144 notice to potentially sell 1,750,000 shares through broker Jefferies LLC on or about 01/22/2026 on the NASDAQ. The filing lists an aggregate market value for the planned sale of $133,525,000.00, based on current market prices, compared with 54,833,587 shares of the class outstanding. The shares were originally purchased in the initial public offering on 07/13/2023 from the issuer for cash, with payment dated 07/18/2023.
By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations, and acknowledges that intentional misstatements or omissions would be a federal criminal violation.
Apogee Therapeutics’ major shareholder Fairmount Funds has updated its ownership disclosure after a sizable share sale. Fairmount Healthcare Fund II L.P. and related parties now report beneficial ownership of up to 9.99% of Apogee’s common stock, using both common and non-voting common shares in the calculation and subject to a 9.99% beneficial ownership cap.
The filing shows Fairmount-related entities having voting and dispositive power over 6,031,979 shares of common stock, including shares issuable upon conversion of non-voting common stock. Fund II also holds 6,743,321 shares of non-voting common stock in total, which can convert to common stock within the ownership limits. On January 22, 2026, Fund II sold 1,750,000 shares of common stock in a block trade at $76.30 per share. Directors Peter Harwin and Tomas Kiselak each hold common shares and vested options but disclaim beneficial ownership of the option shares due to arrangements with Fairmount.
Apogee Therapeutics, Inc. Chief Executive Officer and director Michael Thomas Henderson reported open‑market sales of the company’s common stock. On January 14, 2026, he sold shares in multiple transactions at weighted average prices ranging from about $78.16 to $83.84 per share, under a pre‑arranged Rule 10b5-1 trading plan adopted on August 13, 2025. Following these sales, he reported beneficial ownership of 1,192,987 shares of Apogee common stock held directly.
Apogee Therapeutics, Inc. Chief Medical Officer Carl Dambkowski reported several stock transactions in common shares and options. On January 7, 2026, he exercised a stock option for 14,025 shares of common stock at an exercise price of $22.86 per share, then sold shares in multiple trades: 2,954 shares at $77.13, 14,820 shares at $77.90, 826 shares at $79.04, and 100 shares at $80.06. The sales were executed under a Rule 10b5-1 trading plan adopted on September 22, 2025. After these transactions, he beneficially owned 212,523 shares of common stock and 139,540 stock options. The filing also notes that earlier Forms 4 since October 3, 2025 overstated his beneficial ownership by 53,910 shares due to an administrative error, and this report reflects the corrected amount.
APGE insider Carl Dambkowski has filed a Form 144 to sell 35,200 shares of common stock. The planned sale is through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $2,754,400.00, based on 68,320,229 shares outstanding.
The securities to be sold include 26,400 common shares acquired on 01/07/2026 through the exercise of stock options for cash, and 8,800 common shares originally received as restricted stock awards on 09/16/2022.
Over the past three months, 10b5-1 plan sales for Dambkowski included 10,900 common shares sold on 12/04/2025 for $817,528.34, and additional sales on 11/05/2025 of 8,060 shares for $443,860.98 and 2,725 shares for $150,064.66. By signing, the seller represents they are not aware of undisclosed material adverse information about APGE.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski received a new stock option grant. On January 2, 2026, he was awarded an option to purchase 83,690 shares of Apogee Therapeutics common stock at an exercise price of $75.78 per share. The option was reported as held directly by the officer.
The option will vest in 48 equal monthly installments over four years from the grant date, as long as he continues providing service to the company. The option expires on January 2, 2036, and represents a long-term equity incentive rather than an immediate share purchase.
Apogee Therapeutics’ chief financial officer Jane Henderson reported stock sales and a new stock option grant. On January 2, 2026, she sold 1,920 shares of common stock at a weighted average price of $74.13 and 4,080 shares at a weighted average price of $75.20, under a Rule 10b5-1 trading plan adopted on September 27, 2024. On January 6, 2026, she sold an additional 2,000 shares at $80.00, leaving her with 185,371 common shares held directly.
Separately, on January 2, 2026, she received a stock option to purchase 83,690 shares of common stock at an exercise price of $75.78 per share. This option vests in 48 equal monthly installments over four years from the grant date, subject to her continued service, and is scheduled to expire on January 2, 2036.
Apogee Therapeutics, Inc. reports positive interim Phase 1b data for its anti-IL-13 antibody zumilokibart (APG777) in adults with mild-to-moderate asthma. The double-blind, placebo-controlled study enrolled 31 patients randomized 3:1 to a single 720 mg dose of zumilokibart or placebo, and included a key analysis set of 19 patients with elevated FeNO, a biomarker of Type 2 inflammation. The company also noted observed improvements in asthma and sinusitis symptom scores in its APEX Phase 2 Part A atopic dermatitis trial and highlighted additional data readouts and milestones expected in 2026. Apogee stated it believes it has cash runway into the second half of 2028.
Apogee Therapeutics, Inc. Chief Executive Officer and director Michael Henderson reported insider sales of common stock. On December 10, 2025, he sold a total of 20,000 shares of Apogee common stock in three transactions at weighted-average prices of $74.88, $75.79, and $76.58 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025.
Following these sales, Henderson beneficially owns 1,212,987 shares of Apogee common stock directly. Some of the reported prices represent weighted averages for multiple trades executed within price ranges from $74.30 to $75.29 and from $75.30 to $76.28 per share, and he has agreed to provide detailed trade information to Apogee, any shareholder, or the SEC upon request.
Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, reported a sale of company stock. On December 4, 2025, he sold 10,900 shares of Apogee Therapeutics common stock at a weighted average price of about $75 per share, through multiple transactions between $75.00 and $75.01. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on August 21, 2024. After these sales, he directly beneficially owns 271,108 shares of Apogee Therapeutics common stock.